(IN BRIEF) Evotec SE has announced that Esperion Therapeutics has nominated an oral preclinical development candidate for primary sclerosing cholangitis (PSC), marking a major milestone in their collaboration. The PDC, developed through Evotec’s integrated small molecule discovery platform and Esperion’s … Read the full press release
Posted in Business, Germany, Government, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged ACLY biology, bile ducts, clinical development, collaboration, Cord Dohrmann, drug discovery, Esperion Therapeutics, Evotec Advances Collaboration with Esperion as New ACLY-Based Candidate Targets Primary Sclerosing Cholangitis, Evotec and Esperion Advance Novel Treatment Candidate for Primary Sclerosing Cholangitis, Evotec INDiGO, Evotec SE, fibrosis, Frankfurt Stock Exchange EVT, hepatology, IND-enabling platform, liver disease, milestone payment, NASDAQ ESPR, NASDAQ EVO, preclinical development candidate, primary sclerosing cholangitis, PSC, rare diseases
(IN BRIEF) GSK’s Shingrix vaccine has been approved by China’s NMPA for adults aged 18 and over who are immunocompromised or immunosuppressed, marking the first shingles vaccine available for this group in the country. Affecting about six million people annually … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged CHINA, China National Medical Products Administration, clinical studies, global health, GSK, GSK Expands Shingrix Approval in China to Include Immunocompromised Adults at Risk of Shingles, GSK Strengthens Vaccine Portfolio with Shingrix Approval for High-Risk Adult Populations in China, GSK Wins China Approval for Shingrix in Immunocompromised Adults Expanding Protection Against Shingles, Healthcare, herpes zoster, immunocompromised adults, immunodeficiency, immunosuppression, infectious diseases, NMPA, preventive medicine, public health, Recombinant Zoster Vaccine, RZV, Sanjay Gurunathan, Shingles, Shingrix, vaccine approval, Vaccine Innovation
(IN BRIEF) Researchers at the University of Bristol have developed a promising new gene therapy that could help prevent diabetic kidney disease in people with type 1 diabetes. The treatment uses a harmless virus to deliver the VEGF-C protein directly … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged albuminuria, Aldara Martin Alonso, American Diabetes Association, biomedical research, Bristol Medical School, Chronic kidney disease, diabetes complications, Diabetes UK, Diabetes UK and University of Bristol Study Finds Gene Therapy Could Halt Kidney Disease Progression, diabetic kidney disease, Faye Riley, gene therapy, glomerulus, kidney health, Molecular Therapy, Rebecca Foster, Translational Health Sciences, type 1 diabetes, University of Bristol, University of Bristol Researchers Pioneer New Gene-Based Treatment for Diabetic Kidney Damage, University of Bristol Unveils Gene Therapy Breakthrough to Prevent Kidney Disease in Type 1 Diabetes, VEGF-C
(IN BRIEF) The European Investment Bank and European Commission are jointly supporting BioNTech’s mRNA manufacturing facility in Kigali, Rwanda, with up to €95 million in blended financing. The project aims to strengthen Africa’s capacity to produce vaccines locally for diseases … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Technology
Tagged Africa CDC, African Union, and CEPI Join Forces to Strengthen Africa’s Vaccine Independence Through BioNTech’s Kigali mRNA Facility, BioNTech, BioNTech Secures up to €95 Million in EU and EIB Financing to Boost Vaccine Manufacturing Capacity in Kigali, biotechnology, CEPI, Dr Amadou Sall, EIB, EU, European Commission, European Investment Bank, Global Gateway, HIV, Jozef Sikela, Karl Nehammer, Kigali, local production, malaria, mpox, mRNA Vaccines, public health, Rwanda, Sierk Poetting, Sustainable Healthcare, Team Europe, tuberculosis, Vaccine Innovation, vaccine manufacturing
(IN BRIEF) The Fraunhofer-Gesellschaft has partnered with the Spanish government, Government of Catalonia, and city of Barcelona to establish a joint framework for advancing theranostics research in Spain — a field that combines diagnostics and therapy for personalized medicine. The … Read the full press release
Posted in Business, Germany, Government, News, Pharma & Biotech, Science, Spain, Technology
Tagged bioengineering, biomedical engineering, biotechnology, Catalonia, City of Barcelona, diagnostics, Diana Morant, Europe, Fraunhofer and Catalan Partners Establish Framework for Applied Theranostics Innovation, Fraunhofer and Spanish Partners Unite to Advance Theranostics and Personalized Medicine in Barcelona, Fraunhofer CAT, Fraunhofer Center for Applied Theranostics, Fraunhofer IBMT, Fraunhofer Spain Research Foundation, Fraunhofer-Gesellschaft, Government of Catalonia, Healthcare Innovation, Heiko Zimmermann, Holger Hanselka, IBEC, Jaume Collboni, Josep Samitier, life sciences, New Fraunhofer Initiative in Spain to Drive European Leadership in Theranostics Research, Núria Montserrat Pulido, personalized medicine, Peter Hauptmann, precision medicine, research collaboration, Salvador Illa, Spain and Germany Strengthen Research Ties Through New Fraunhofer Center for Theranostics in Barcelona, Spanish government, theranostics, therapy
(IN BRIEF) A new study led by researchers at The Institute of Cancer Research, London, has identified a promising new combination therapy for pancreatic cancer that could transform future treatment. The dual approach — combining boiling histotripsy and oncolytic reovirus … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged boiling histotripsy, cancer research, cancer treatment innovation, Gail ter Haar, ICR, ICR study identifies new immune-based combination strategy to improve pancreatic cancer treatment outcomes, immune response, immunotherapy, Institute of Cancer Research, macrophages, neutrophils, oncolytic reovirus, pancreatic cancer, Pancreatic cancer study from ICR highlights new dual treatment approach and reveals key immune cell insights, Pancreatic Cancer UK, Petros Mouratidis, Pharmaceutics, preclinical study, The Institute of Cancer Research identifies promising dual treatment strategy for pancreatic cancer, tumour microenvironment, ultrasound therapy, viral immunotherapy
(IN BRIEF) The Institute of Cancer Research has renewed its Athena Swan Silver Award for 2025–2029, recognising continued progress in promoting gender equality and fostering an inclusive workplace. The award highlights key achievements such as improved recruitment and flexible working … Read the full press release
Posted in Business, Education, Healthcare, Management, News, Pharma & Biotech, Science, Society, Technology, United Kingdom
Tagged academic leadership, Advance HE, Alan Cumber, and research culture, Athena Swan action plan, Athena Swan Silver Award, career development, diversity, Diversity And Inclusion, Dr Barbara Pittam, equity in research, flexible working, gender equality, Gender Pay Gap, higher education, ICR, ICR recognised for advancing inclusive excellence with Athena Swan Silver Award renewal through 2029, ICR secures four-year Athena Swan Silver Award recognising progress in equity, Institute of Cancer Research, Institute of Cancer Research celebrates renewed Athena Swan Silver Award with new gender equality action plan, Pathway to Independence program, Professor Christina Yap, Professor Kristian Helin, research culture, Technician Career Pathways
Europe’s RNA immunotherapy sector is gaining speed with new in vivo CAR-T and mRNA vaccine trials. Germany approved the region’s first in vivo CAR-T study, marking regulatory progress. The UK’s Cancer Vaccine Launch Pad advances personalised mRNA cancer vaccine trials … Read the full press release
Posted in Belgium, Business, Germany, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, ATMP, autoimmunity, BioNTech, BioNTech’s BNT116, biotechnology, Cancer Vaccine Launch Pad, CAR-T therapy, clinical trials, CREATE Medicines, CureVac, EMA, EU-FAB, Europe, Europe Becomes a Hub for Next-Generation RNA Immunotherapy with Strong Clinical and Industrial Momentum, Europe’s Biotech Sector Accelerates RNA-Based Immunotherapy with Breakthroughs in CAR-T and mRNA Vaccines, Europe’s RNA Immunotherapy Industry Poised for Expansion as BioNTech AstraZeneca and CREATE Medicines Lead Advances, Europe’s RNA Immunotherapy Landscape Expands with First In Vivo CAR-T Trial and Growing mRNA Vaccine Efforts, Europe’s RNA Immunotherapy Pipeline Gains Scale as Regulators and Industry Push for Next-Gen Cancer Treatments, fibrosis, Germany, Imfinzi, immuno-oncology, in vivo CAR-T, INT2104, mRNA Vaccines, multi-lineage immune programming, Myeloid Therapeutics, NHS England, oncology, pharma, RNA immunotherapy, RNA Immunotherapy in Europe: Emerging Trials Strategic Mergers and a Clearer Regulatory Path, RNA Immunotherapy Takes Hold in Europe as BioNTech-CureVac Deal and CREATE Medicines Expansion Signal Maturity, RNA therapeutics, RNA-based therapies, United Kingdom
Rebrand: Myeloid Therapeutics becomes CREATE Medicines, reflecting a shift to multi-lineage RNA immune programming. Scientific Focus: Expanding beyond myeloid cells to include T and NK cells for scalable, redosable in vivo CAR therapies. Clinical Data: Over 40 patients treated with … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, CREATE Medicines Bridges Science Strategy and Investment with Expanded RNA Platform for In Vivo Multi-Immune Therapies in Europe and Beyond, CREATE Medicines Integrates Scientific Progress and Investor Backing to Lead Multi-Lineage RNA Immunotherapy’s Next Chapter in Europe, CREATE Medicines Rebrand Reflects Strategic Expansion into Multi-Lineage RNA Immunotherapy as Europe’s Biotech Sector Embraces In Vivo Therapies, CREATE Medicines Reinforces Its Market and Research Focus Through RNA-Driven Multi-Lineage Immune Programming Amid Rising European Investment in mRNA Therapeutics, CREATE Medicines Strengthens Its Scientific and Strategic Position with Multi-Lineage RNA Platform and Investor Support Across a Growing European Biotech Market, CREATE Medicines’ New Identity Combines RNA-Based Scientific Leadership and Investor Momentum with Expanding Opportunities in European Immunotherapy Markets, CREATE Medicines’ Transition Marks New Phase in RNA Immunotherapy Development and Strategic Growth in Europe’s Expanding Biotech Landscape, Daniel Getts, Daniel Getts Ph.D., fibrosis, Following Its Rebrand, From Myeloid Therapeutics to CREATE Medicines: A Rebrand Uniting RNA Innovation Investor Confidence and Expanding European Immunotherapy Ambitions, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, himeric antigen receptor, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, Rebranded CREATE Medicines Aligns Scientific Innovation and Investor Backing to Advance RNA-Based In Vivo CAR Therapies in Global and European Markets, Rebranded CREATE Medicines Positions Itself at the Forefront of RNA Immunotherapy as Europe’s Biotech Ecosystem Accelerates Innovation, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
(IN BRIEF) AstraZeneca reported positive Phase III Bax24 trial results showing that baxdrostat achieved a significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in patients with treatment-resistant hypertension. The once-daily oral therapy was well tolerated and maintained … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Advancing Toward Regulatory Submission, AHA 2025, aldosterone, aldosterone synthase inhibitor, ambulatory blood pressure, American Heart Association, AstraZeneca, AstraZeneca’s Baxdrostat Achieves Significant Blood Pressure Reduction in Phase III Bax24 Trial, AstraZeneca’s Baxdrostat Achieves Strong Blood Pressure Reduction in Phase III Bax24 Trial for Resistant Hypertension, Bax24, Baxdrostat, Baxdrostat Delivers Significant 24-Hour Blood Pressure Control in Phase III Study, BaxHTN, Bryan Williams, cardiovascular health, Chronic kidney disease, clinical trial, heart failure prevention, Hypertension Treatment, Phase III results, primary aldosteronism, resistant hypertension, rHTN, SBP, Sharon Barr, systolic blood pressure
CREATE Medicines (“CREATE”) broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, providing clear differentiation among competitors and significant value potential for all stakeholders CREATE Medicines will … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology
Tagged 8VC, ARCH Venture Partners, autoimmunity, B-cell depletion, biopsies, Biotech, biotechnology, breast cancer, cancer therapy, CAR+ immune cells, CD8 T cell recruitment, clinical trials, CREATE Medicines, Daniel Getts, Daniel Getts Ph.D., fibrosis, GPC3, GPC3-positive solid tumors, GPC3; hepatocellular carcinoma, Hatteras Venture Partners, HER2, HER2 multi-immune CAR, HER2; solid tumors, immune cell reprogramming, immune cells, immune remodeling, immunotherapies, immunotherapy, in vivo CAR, in vivo CAR-T mediated B cell depletion, in vivo multi-immune programming, mRNA, mRNA-LNP platform, MT-302, MT-303, MT-304, multi-immune programming, multilineage immune programming, myeloid, myeloid cells, Myeloid Therapeutics, myeloid-focused in vivo programming, Newpath Partners, NK cell programming, NK cells, off-the-shelf therapies, oncology, Phase 1 studies, retrotransposon-based CAR-T, RNA retrotransposon, RNA technology, RNA-based in vivo CAR therapeutics, RNA-based therapeutics, solid tumors, T cells, therapies, TROP2, TROP2; solid tumors, tumors, vivo CAR, vivo CAR-T
(IN BRIEF) The University of Twente, Medisch Spectrum Twente, and the Centre for Human Drug Research (CHDR) will open a new clinical research unit at MST on 10 October 2025. This expansion represents CHDR’s first facility outside Leiden and underscores … Read the full press release
Posted in Education, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Centre for Human Drug Research, Centre for Human Drug Research opens new clinical unit at Medisch Spectrum Twente in partnership with University of Twente, CHDR, clinical research, clinical trials, drug development, Enschede, Healthcare Innovation, Leiden BioScience Park, Leiden University, Leiden University Medical Centre, medical technology, Medisch Spectrum Twente, MST, New clinical research unit at MST marks next step in partnership between University of Twente and Centre for Human Drug Research, TechMed Centre, therapeutic innovation, Twente, University of Twente, University of Twente and partners launch new Centre for Human Drug Research clinical research unit to advance therapeutic innovation in Twente, University of Twente joins CHDR and MST to position Twente as a hub for medical technology and therapeutic development, University of Twente joins forces with CHDR and Medisch Spectrum Twente to open new clinical research unit in Twente, UT
(IN BRIEF) The Institute of Cancer Research and NEOsphere Biotechnologies have announced a new collaboration to accelerate the discovery of molecular glue degrader drugs, an innovative approach in targeted cancer therapy. The partnership will integrate ICR’s proprietary molecular glue library … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academic–industry partnership to accelerate rational design of molecular glue degrader drugs for cancer treatment, artificial intelligence, Cancer Drug Discovery, cancer research innovation, Centre for Protein Degradation, computational drug design, E3 ligases, Henrik Daub, high-throughput proteomics, ICR, ICR and NEOsphere Biotechnologies join forces to pioneer systematic discovery of molecular glue degrader therapies, Institute of Cancer Research, Institute of Cancer Research and NEOsphere Biotechnologies partner to advance molecular glue degrader drug discovery, Jonathan Beech, Machine Learning, MGDs, molecular glue degraders, molecular glue library, Monte Rosa Therapeutics, Nature Communications, NEOsphere Biotechnologies, Novartis, proteomics, St Jude Children’s Research Hospital, targeted protein degradation, Zoran Rankovic
(IN BRIEF) CapMan Buyout has sold Pharmia Holding Oy, the leading Nordic contract manufacturer of dietary supplements and medical devices, to Labomar, an Italy-based European group owned by Charterhouse Capital Partners. Since CapMan’s investment in 2021, Pharmia has grown into … Read the full press release
Posted in Business, Financial, Finland, Investment, Management, News, Pharma & Biotech, Sweden
Tagged acquisition, Anders Björkell, CANADA, CapMan Buyout, CapMan exits Pharmia as Finnish dietary supplements leader joins Labomar to expand Nordic presence, Charterhouse Capital Partners, contract manufacturing, dietary supplements, Finland, functional cosmetics, health and wellness industry, Italy, Labomar, M&A, medical devices, Nordic market, Petteri Laaksomo, Pharmia Holding Oy, Pharmia sold by CapMan to Labomar as part of strategic expansion in Nordic dietary supplements and medical devices, probiotics, R&D, Spain, Walter Bertin
(IN BRIEF) Scientists at the University of Liverpool have developed two new handheld blood test devices that could make Alzheimer’s disease testing faster, cheaper, and more widely accessible. By combining polymer-based biosensors with AI, the devices can detect the Alzheimer’s … Read the full press release
Posted in Artificial Intelligence (AI), Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ACS Sensors, Advanced Healthcare Materials, AI, Alzheimer’s disease, AMED, artificial intelligence, biosensors, blood test, dementia, Department of Pharmacology and Therapeutics, Dr Sanjiv Sharma, Early Detection, Faculty of Health and Life Sciences, Healthcare Accessibility, Institute of Systems Molecular and Integrative Biology, low-cost diagnostics, molecularly imprinted polymers, MRC, p-tau181, Scientists at University of Liverpool develop portable blood test to expand Alzheimer’s screening access, SIMOA, UK Japan collaboration, University of Liverpool, University of Liverpool scientists pioneer affordable blood test for early Alzheimer’s detection, University of Liverpool unveils affordable handheld blood test for early Alzheimer’s detection, WHO
(IN BRIEF) Novartis, through its wholly owned subsidiary Torino Merger Sub Inc., has launched a tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at USD 48 per share in cash. The offer commenced September 29, 2025, and … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, biopharma acquisition, Computershare Trust Company, Hart-Scott-Rodino Act, Innisfree M&A, M&A, Merger Agreement, Novartis, Novartis Commences Tender Offer to Acquire Tourmaline Bio for USD 48 Per Share, Novartis Moves Forward with Acquisition of Tourmaline Bio Through Tender Offer, Novartis Pursues Strategic Acquisition of Tourmaline Bio with USD 48 Per Share Tender, Schedule 14D-9, Schedule TO, SEC filing, shareholder offer, tender offer, Torino Merger Sub, Tourmaline Bio, USD 48 per share
(IN BRIEF) Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% discount off list price for cash-paying patients. Cosentyx, a biologic approved for multiple immune-mediated … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, Switzerland
Tagged biologics, Cosentyx, direct-to-employer model, direct-to-patient platform, discount medicines, drug affordability, DTP, hidradenitis suppurativa, immune-mediated inflammatory diseases, New Direct-to-Patient Platform from Novartis Aims to Reduce Barriers and Improve Affordability, Novartis, Novartis Launches Direct-to-Patient Platform in US with Discounted Access to Cosentyx, Novartis to Provide Patients Direct Access to Lower-Priced Cosentyx Starting November 2025, NPAF, patient access, patient assistance, psoriasis, psoriatic arthritis, secukinumab, specialty medicines, US healthcare, Victor Bultó
(IN BRIEF) The Royal Devon University Healthcare NHS Foundation Trust and the University of Exeter have launched the RAPID-IBD study to speed up diagnosis of Crohn’s disease and ulcerative colitis, conditions that affect 1 in 100 people in the UK. … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Sports, Technology, United Kingdom
Tagged Catherine Winsor, Crohn's disease, Crohn’s & Colitis UK, early diagnosis, EX postcode, Exeter City FC, gut health, IBD, inflammatory bowel disease, Jack Fitzwater, Know Your Sh*t campaign, Know Your Sh*t Campaign Backs Exeter-Led Study to Improve Early Detection of IBD in Young People, New Exeter Research Aims to Transform Diagnosis and Treatment Pathways for Crohn’s and Colitis, NIHR, patient volunteers, RAPID-IBD, RAPID-IBD Research Project Invites Volunteers to Speed Up Diagnosis of Inflammatory Bowel Disease, Royal Devon University Healthcare NHS Foundation Trust, stool test, Tariq Ahmad, Ulcerative colitis, University of Exeter
(IN BRIEF) A research team at the MRC–University of Glasgow Centre for Virus Research has launched Viro3D, the world’s most extensive AI-powered database of virus protein structure predictions. Containing 85,000 protein models from 4,400 human and animal viruses, Viro3D expands … Read the full press release
Posted in Artificial Intelligence (AI), Education, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 000 structural models, AI powered database, AI-powered Viro3D expands virus protein knowledge thirtyfold with 85, AlphaFold, antivirals, Centre for Virus Research, common cold, COVID 19, Evolutionary Scale Modelling Metagenomic Atlas, hepatitis, herpesvirus, HIV, Joe Grove, Medical Research Council, Medical Research Foundation, Molecular Systems Biology, MRC, SARS-CoV-2, the largest AI-driven database of virus protein structures, the world’s largest AI-powered virus protein database, University of Glasgow, University of Glasgow researchers unveil Viro3D, University of Glasgow scientists launch Viro3D, vaccines, Viro3D, Viro3D launches as a new AI-powered platform to transform virus research and drug discovery worldwide, Viro3D sheds light on virus evolution and ancestry with the world’s most comprehensive protein structure predictions, virus evolution, virus protein structures, virus research, Wellcome
(IN BRIEF) The Institute of Cancer Research, London, has uncovered a promising new treatment target for pancreatic cancer, identifying the protein SPP1 as a driver of tumour spread and poor survival. In studies using tumour samples, organoids, and animal models, … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Blocking SPP1 shown to stop tumour spread and extend survival in pancreatic ductal adenocarcinoma, The Institute of Cancer Research identifies SPP1 protein as new drug target to halt aggressive pancreatic cancer
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?